10x Genomics Collaborates with Brigham & Women's Hospital to Analyze Blood Samples for Autoimmune Diseases
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
10x Genomics announced a collaboration with Brigham & Women's Hospital to analyze peripheral blood samples from patients living with rheumatoid arthritis, systemic lupus erythematosus and giant cell arteritis to uncover immune signatures associated with disease activity, flare, remission and therapeutic response. As part of this effort, 10x and Brigham & Women's Hospital also plan to build a framework for a future clinical report, defining how blood-based molecular features, such as immune activation patterns or markers of disease trajectory, could be translated into a clear, clinically relevant summary to support physicians as they evaluate disease activity and plan treatments for autoimmune disease.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on TXG
Wall Street analysts forecast TXG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TXG is 13.00 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 21.080
Low
9.00
Averages
13.00
High
18.00
Current: 21.080
Low
9.00
Averages
13.00
High
18.00
About TXG
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
- Technological Acceleration: Ark Invest's report highlights that capital investment in disruptive innovation platforms could contribute 1.9 percentage points to annualized real GDP growth during this decade, emphasizing the potential of technologies like robotaxis and next-gen data centers.
- Strong ETF Performance: In 2025, Ark's Autonomous Technology & Robotics ETF and Space & Defense Innovation ETF achieved returns of 49.8% and 49.2%, respectively, showcasing the firm's ability to generate returns in emerging technology sectors.
- Bitcoin Holdings Surge: The report indicates that U.S. ETFs and public companies now hold 12% of total Bitcoin supply, with Bitcoin ETF balances up 19.7% and public company Bitcoin holdings up 73% in 2025, reflecting strong market demand for digital assets.
- Diverse Investment Opportunities: Ark Invest identifies several publicly traded companies, including Coinbase, Illumina, and Waymo, as key investment opportunities for the 2026 themes, indicating the firm's forward-looking approach to diversified investment strategies.
Continue Reading
Ark Invest Unveils 2026 Big Ideas, Focus on AI and Genomics
- AI Agents Theme: Ark Invest's first ARKmoji hints at agentic AI, with users divided on its meaning; the option 'AI Agent Takeover' received 37.5% support, indicating strong market interest in AI technologies that could impact stocks like Palantir.
- Genomics Potential: The second ARKmoji features a DNA helix, with 34.7% of votes for 'Molecular Diagnostics', highlighting investment opportunities in genomics, potentially benefiting related stocks like Crispr Therapeutics.
- Space Race Trend: The third ARKmoji depicts a rocket, with 55% of users selecting 'Reusable Rockets', reflecting enthusiasm for space technology investments, with holdings like Rocket Lab poised for growth.
- Robotics Development: The final ARKmoji shows a robot, with 59% voting for the 'Robotics' theme, indicating strong market interest in robotics technology, with Tesla's Optimus robot project likely to be a future growth driver.
Continue Reading